SOPHiA GENETICS CEO sells 422 shares at $8.33

SOPHiA GENETICS SA’s CEO reported a small Rule 10b5-1 tax-withholding share sale and continues to hold over 670,000 shares.

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) reported that Chief Executive Officer and director Ross Muken sold 422 Ordinary Shares on September 21, 2026 at $8.33 per share. According to the disclosure, the shares were sold in the open market solely to satisfy tax withholding obligations from restricted stock units that vested on September 18, 2026, under a pre-established Rule 10b5-1(c) trading plan, and are not discretionary trades. Following this transaction, Muken directly holds 670,229 Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 422 shares

Net Sell 1 txn

Insider Muken Ross

Role Chief Executive Officer

Sold 422 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1	422	$8.33	$4K

Holdings After Transaction: Ordinary Shares — 670,229 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on September 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

Key Figures

Shares sold: 422 shares Sale price per share: $8.33 per share Shares owned after transaction: 670,229 shares

3 metrics

Shares sold 422 shares Ordinary Shares sold on September 21, 2026

Sale price per share $8.33 per share Open-market sale on September 21, 2026

Shares owned after transaction 670,229 shares Direct holdings of CEO Ross Muken following the sale

Key Terms

Rule 10b5-1(c) trading plan, restricted stock units, tax withholding obligations

3 terms

Rule 10b5-1(c) trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan"

A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.

restricted stock units financial

"arising in connection with the vesting of restricted stock units on September 18, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold ... to satisfy tax withholding obligations arising in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPH report for CEO Ross Muken?

SOPHiA GENETICS SA reported that CEO Ross Muken sold 422 Ordinary Shares on September 21, 2026 at $8.33 per share, in an open-market transaction tied to tax withholding from vested restricted stock units.

How many SOPH shares does the CEO hold after this Form 4 transaction?

After the reported sale, CEO Ross Muken directly holds 670,229 Ordinary Shares of SOPHiA GENETICS SA, according to the filing.

Why did the SOPH CEO sell 422 shares in this filing?

The 422 shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units on September 18, 2026, as stated in the footnote.

Was the SOPH CEO’s share sale part of a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the reporting person and did not represent discretionary trades.

What was the price of the SOPH shares sold by the CEO?

The 422 Ordinary Shares were sold at a price of $8.33 per share on September 21, 2026, described as a sale in the open market or a private transaction.

How many shares in total were sold in this SOPH Form 4?

The Form 4 reports a single transaction in which 422 Ordinary Shares of SOPHiA GENETICS SA were sold by the CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 04:02 PM Accepted by SEC EDGAR 09/22/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muken Ross

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/21/2026		S		422(1)	D	$8.33	670,229	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on September 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)